On Thursday, Shares of Vale S.A. (NYSE:VALE), gained 3.11% to $4.98, after the company was granted permission to reopen a nickel mine in Brazil, Reuters reports.
The Brazilian mining company was ordered to halt operations by a Brazilian court at the Onça Puma nickel mine, in the Amazonian state of Pará, in mid-August and was ordered to pay about $287,000 to each indigenous village in the area.
Vale said a court ruled in its favor and suspended the 3 million reais compensation for the surrounding communities, Reuters added.
Vale S.A., together with its auxiliaries, engages in the research, production, and sale of iron ore and pellets, nickel, fertilizer, copper, coal, manganese, ferroalloys, cobalt, platinum group metals, and precious metals in Brazil and internationally.
Shares of Mylan N.V. (NASDAQ:MYL), declined -2.47% to $47.42, during its last trading session.
Mylan declared that the U.S. Patent and Trademark Office (PTO) has instituted an inter partes review (IPR) proceeding on all claims against a third Copaxone® 40 mg/mL patent, U.S. Patent No. 8,969,302, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. The patent relates to methods for the treatment of multiple sclerosis through the administration of at least three 40 mg/mL subcutaneous injections of glatiramer acetate per week.
On Aug. 25, 2015, Mylan declared that the PTO instituted IPR proceedings against two related Copaxone® 40 mg/mL patents, U.S. Patent Nos. 8,232,250 and 8,399,413, on all claims. The oral hearing for all three IPRs has been planned for May 12, 2016.
In August 2014, the U.S. Food and Drug Administration accepted Mylan’s abbreviated new drug application (ANDA) filing for a three times per week Glatiramer Acetate Injection 40 mg/mL, the generic version of Copaxone 40 mg/mL Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and anticipates to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval.
Copaxone 40 mg/mL had U.S. sales of about $2.6 billion for the 12 months ending June 30, 2015, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, American Express Company (NYSE:AXP), ended its last trade with 0.43% gain, and closed at $75.26.
American Express Company Chief Financial Officer, Jeffrey C. Campbell, will present at the Barclays Global Financial Services Conference in New York City, on Friday, September 18, 2015, at 11:15 a.m. (ET). Mr. Campbell’s presentation will be focused on the Company’s business strategy and financial performance. After the presentation, Mr. Campbell will take part in a question-and-answer session.
American Express Company, together with its auxiliaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide. The company operates through four segments: U.S. Card Services, International Card Services, Global Commercial Services, and Global Network & Merchant Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
